NovoCure Ltd. (NVCR) PT Lowered to $95 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NVCR Hot Sheet
Price: $14.61 +8.79%
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 13 | New: 1
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 13 | New: 1
Join SI Premium – FREE
Truist Securities analyst Gregory Fraser lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $95.00 (from $102.00) while maintaining a Buy rating.
You May Also Be Interested In
- Precigen Inc. (PGEN) PT Raised to $12 at Citizens on 'Stellar Quarter for PAPZIMEOS'
- Arbonia AG (ARBN:SW) PT Lowered to CHF5.40 at UBS
- Encore Capital Inc. (ECPG) PT Raised to $140 at Citizens on Material Upside to EPS, KPI Estimates
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
